Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the

First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743 - Annals of Oncology

Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain

Nivolumab (Opdivo) Drug Information

Nivolumab in Combination With Ipilimumab in BRAF V600 Wild-Type Unresectable or Metastatic Melanoma - The ASCO Post

Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial

OPDIVO® (nivolumab) + YERVOY® (ipilimumab) Efficacy in Metastatic Melanoma

Advances in targeted therapy and immunotherapy for melanoma (Review)

Frontiers Nivolumab plus ipilimumab in metastatic melanoma: a critical appraisal focused on specific subpopulations

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial - The Lancet Oncology

Looking into a Better Future: Novel Therapies for Metastatic Melanoma

Figure 3 from Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

The New England Journal of Medicine - In patients with untreated metastatic melanoma, the addition of ipilimumab (anti-CTLA4) to nivolumab (anti-PD1) did not further improve response rate or progression-free survival in PD-L1